menu search

Acceptance of polyamine inhibitor car-t combination abstract for online publication

MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

October 25, 2023, 12:15 pm

Panbela announces poster presentation at the endocrine society meeting: polyamine inhibition and β-cell preservation in recent onset type 1 diabetes

MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disru...

June 26, 2023, 12:15 pm

Panbela announces sponsored research agreement to evaluate polyamine metabolic inhibitor therapy in combination with car-t cell therapy

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutic...

June 13, 2023, 12:15 pm


Search within

Pages Search Results: